Russell Zelig Szmulewitz (Russell Z Szmulewitz, Russell Szmulewitz)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 14

Top Topics

Anti Inflammatory Drugs

Circulating Tumor

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Maha H A Hussain, Masha Kocherginsky, Archana M Agarwal, Nabil Adra, Jingsong Zhang, Channing J Paller, Joel Picus, Zachery R Reichert, Russell Zelig Szmulewitz, Scott T Tagawa, Timothy M Kuzel, Latifa A Bazzi, Stephanie Daignault-Newton, Young E Whang, Robert Dreicer, Ryan D Stephenson, Matthew B Rettig, Daniel Shevrin, Travis A Gerke, Arul M Chinnaiyan, Emmanuel S Antonarakis
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P McDonnell, John D Norris, Changxue Lu, Jun Luo, Andrew J Armstrong
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (6) (2024)
Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P McDonnell, John D Norris, Changxue Lu, Jun Luo, Andrew J Armstrong
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (6) (2024)
Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P McDonnell, John D Norris, Changxue Lu, Jun Luo, Andrew J Armstrong
The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (6) (2024)
Susan Halabi, Siyuan Guo, Joseph J Park, David M Nanus, Daniel J George, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Donald P McDonnell, John D Norris, Changxue Lu, Jun Luo, Andrew J Armstrong
The impact of circulating tumor cell HOXB13 RNA detection in men with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Kunal B Desai, Anthony V Serritella, Walter M Stadler, Peter H O'Donnell, Randy F Sweis, Russell Zelig Szmulewitz
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (11) (2024)
Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J George, David M Nanus, Emmanuel S Antonarakis, Daniel Costin Danila, Russell Zelig Szmulewitz, Richard Wenstrup, Andrew J Armstrong
PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Lynda Bennett, Praveen Kumar Jaiswal, Ryan V Harkless, Tiha M Long, Ning Gao, Brianna Vandenburg, Phillip Selman, Ishrat Durdana, Ricardo R Lastra, Donald J Vander Griend, Remi Adelaiye-Ogala, Russell Zelig Szmulewitz, Suzanne D Conzen
Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer. Molecular cancer therapeutics (2023)
Zachary Quinn, Benjamin E Leiby, Guru P Sonpavde, Atish D Choudhury, Christopher J Sweeney, David J Einstein, Russell Zelig Szmulewitz, A Oliver Sartor, Beatrice Knudsen, Eddy Shih-Hsin Yang, William Kevin Kelly
Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)